Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus

Circulation

Volumn 122, Issue 11 SUPPL. 1, 2010, Pages

  Chu, Louis M ^a   Osipov, Robert M ^a   Robich, Michael P ^a   Feng, Jun ^a   Sheller, Michael R ^c   Sellke, Frank W ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

^c Capstone Therapeutics   (United States)

Author keywords

diabetes mellitus; ischemia; pharmacology; reperfusion

Indexed keywords

ALLOXAN; CASPASE 3; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PROTEIN TP508; TETRAZOLIUM; THROMBIN; UNCLASSIFIED DRUG; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PEPTIDE FRAGMENT; PROTEIN SERINE THREONINE KINASE; RUSALATIDE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CORONARY ARTERY LIGATION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; ANIMAL; APOPTOSIS; CORONARY ARTERY BLOOD FLOW; CORONARY BLOOD VESSEL; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM; FEMALE; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PATHOPHYSIOLOGY; SWINE;

ANIMALS; APOPTOSIS; CASPASE 3; CELL SURVIVAL; CORONARY CIRCULATION; CORONARY VESSELS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ENDOTHELIUM; FEMALE; GLYCOGEN SYNTHASE KINASE 3; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MYOCARDIAL REPERFUSION INJURY; PEPTIDE FRAGMENTS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SWINE; THROMBIN; VENTRICULAR FUNCTION, LEFT; TOR SERINE-THREONINE KINASES;

EID: 77957241160     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.928374     Document Type: Article

References (27)

1. Jugdutt BI. Nitric oxide and cardioprotection during ischemia- reperfusion. Heart Fail Rev. 2002;7:391-405.
2. Ely SW, Berne RM. Protective effects of adenosine in myocardial ischemia. Circulation. 1992;85:893-904.
3. Kopecky SL, Aviles RJ, Bell MR, Lobl JK, Tipping D, Frommell G, Ramsey K, Holland AE, Midei M, Jain A, Kellett M, Gibbons RJ. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angio-plasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J. 2003;146:146-152.
4. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intra-coronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000;101:2154-2159.
5. Glenn KC, Frost GH, Bergmann JS, Carney DH. Synthetic peptides bind to high-affinity thrombin receptors and modulate thrombin mitogenesis. Pept Res. 1988;1:65-73.
6. Tsopanoglou NE, Papaconstantinou ME, Flordellis CS, Maragoudakis ME. On the mode of action of thrombin-induced angiogenesis: thrombin peptide, TP508, mediates effects in endothelial cells via av/33 integrin. Thromb Haemost. 2004;92:846-857.
7. Wang H, Li X, Tomin E, Doty SB, Lane JM, Carney DH, Ryaby JT. Thrombin peptide (TP508) promotes fracture repair by up-regulating inflammatory mediators, early growth factors, and increasing angiogenesis. J Orthop Res. 2005;23:671-679.
8. Norfleet AM, Bergmann JS, Carney DH. Thrombin peptide, TP508, stimulates angiogenic responses in animal models of dermal wound healing, in chick chorioallantoic membranes, and in cultured human aortic and microvascular endothelial cells. Gen Pharmacol. 2000;35: 249-254.
9. Carney DH, Olszewska-Pazdrak B. Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair? Expert Opin Pharmacother. 2008;9:2717-2726.
10. Osipov RM, Bianchi C, Clements RT, Feng J, Liu Y, Xu SH, Robich MP, Wagstaff J, Sellke FW. Thrombin fragment (TP508) decreases myocardial infarction and apoptosis after ischemia reperfusion injury. Ann Thorac Surg. 2009;87:786-793.
11. Osipov RM, Robich MP, Feng J, Clements RT, Liu Y, Glazer HP, Wagstaff J, Bianchi C, Sellke FW. Effect of thrombin fragment (TP508) on myocardial ischemia-reperfusion injury in hypercholesterolemic pigs. J Appl Physiol. 2009;106:1993-2001.
12. Osipov RM, Bianchi C, Feng J, Liu Y, Robich MP, Glazer HP, Sodha NR, Sellke FW. Effect of hypercholesterolemia on myocardial necrosis and apoptosis in the setting of ischemia-reperfusion. Circulation. 2009; 120:22-30.
13. Sodha NR, Clements RT, Feng J, Liu Y, Bianchi C, Horvath EM, Szabo C, Sellke FW. The effects of therapeutic sulfide on myocardial apoptosis in response to ischemia-reperfusion injury. Eur J Cardiothorac Surg. 2008;33:906-913.
14. Singla DK, Kaur K, Sharma AK, Dhingra S, Singal PK. Probucol promotes endogenous antioxidant reserve and confers protection against reperfusion injury. Can J Physiol Pharmacol. 2007;85:439-443.
15. Zhao N, Liu YY, Wang F, Hu BH, Sun K, Chang X, Pan CS, Fan JY, Wei XH, Li X, Wang CS, Guo ZX, Han JY. Cardiotonic pills, a compound Chinese medicine, protects ischemia-reperfusion-induced microcircu-latory disturbance and myocardial damage in rats. Am J Physiol Heart Circ Physiol. 2010;298:H1166- H1176.
16. Quintana M, Kahan T, Hjemdahl P. Pharmacological prevention of reperfusion injury in acute myocardial infarction: a potential role for adenosine as a therapeutic agent. Am J Cardiovasc Drugs. 2004;4:159-167.
17. Chu LM, Osipov RM, Robich MP, Feng J, Bianchi C, Oyamada S, Sellke FW. Is hyperglycemia bad for the heart during acute ischemia? J Thorac Cardiovasc Surgy. 2010; In press.
18. Manning AS, Hearse DJ. Reperfusion-induced arrhythmias: mechanisms and prevention. J Mol Cell Cardiol. 1984;16:497-518.
19. Zakeri Z, Lockshin RA. Cell death: history and future. Adv Exp Med Biol. 2008;615:1-11.
20. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008;88: 581-609.
21. Uchiyama T, Engelman RM, Maulik N, Das DK. Role of Akt signaling in mitochondrial survival pathway triggered by hypoxic preconditioning. Circulation. 2004;109:3042-3049.
22. Tong H, Imahashi K, Steenbergen C, Murphy E. Phosphorylation of glycogen synthase kinase-3/3 during preconditioning through a phosphatidylinositol-3- kinase-dependent pathway is cardioprotective. Circ Res. 2002;90:377-379.
23. Murphy E, Steenbergen C. Inhibition of GSK-3/3 as a target for cardio-protection: the importance of timing, location, duration and degree of inhibition. Expert Opin Ther Targets. 2005;9:447-456.
24. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase/3inhibition during reperfusion in intact rat hearts. Circ Res. 2004;94:960-966.
25. Olszewska-Pazdrak B, Hart-Vantassell A, Carney DH. Thrombin peptide TP508 stimulates rapid nitric oxide production in human endothelial cells. J Vasc Res. 2009;47:203-213.
26. Fossum TW, Olszewska-Pazdrak B, Mertens MM, Makarski LA, Miller MW, Hein TW, Kuo L, Clubb F, Fuller GM, Carney DH. TP508 (Chrysalin) reverses endothelial dysfunction and increases perfusion and myocardial function in hearts with chronic ischemia. J Cardiovasc Pharmacol Ther. 2008;13:214-225.
27. Derkach DN, Wadekar SA, Perkins KB, Rousseau E, Dreiza CM, Cheung-Flynn J, Ramos HC, Ugarova T, Sheller MR. RGD-dependent bindingn of TP508 to integrin avB3 mediates cell adhesion and induction of nitric oxide. Thromb Haemost. 2010;104:172-182.